TNF and rheumatoid arthritis: In a recently published safety profile study in patients with RA, an increased risk of VTEs was seen in subjects treated with tofacitinib than in those given TNF inhibitors; however, it is important to note that this applied exclusively to patients beyond the age of 50 years, who presented with at least one cardiovascular risk factor.